news
Moonwalk Biosciences raised $70M for fat-targeted RNAi drug
Moonwalk Biosciences secured $70 million in Series B funding to develop an RNAi drug targeting fat cells without affecting appetite. The biotech aims to reduce fat mass while preserving lean muscle, with human trials starting in late 2027. This is for people who want to lose fat but not the muscle that comes with current weight-loss options.
Moonwalk Biosciences secured $70 million in Series B funding to develop an RNAi drug targeting fat cells without affecting appetite. The biotech aims to reduce fat mass while preserving lean muscle, with human trials starting in late 2027. This is for people who want to lose fat but not the muscle that comes with current weight-loss options.
The architecture take
Everyone's talking GLP-1s for weight loss, but this is a totally different game. Moonwalk just raised $70 million for an RNAi drug that directly targets adipose (fat) tissue. The mechanism isn't about appetite suppression, which is what makes GLP-1s work; instead, it's about messing with gene expression specifically in fat cells to reduce them while leaving your muscle mass alone. That's the real kicker here. If they pull this off in human trials by late 2027, it means a path to fat loss without the loss of lean tissue and the accompanying metabolic slowdown that usually happens with dieting or even GLP-1s. It shifts the entire conversation from 'eat less' to 'reprogram fat.' What this means for your body is a potential future where fat loss doesn't mean fighting hunger or sacrificing strength. Watch this space, because it could fundamentally change how we think about body composition and metabolic health, especially for maintaining a good resting metabolism long-term.